In this episode, you'll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, chief medical officer at VectorY Therapeutics. We'll be speaking about patient-pharma collaborations accelerating trials and hope, advances in ALS biology understanding and biomarker-driven endpoints. Host<a href="https://www.linkedin.com/in/jennifersmithparker/" rel="noopener noreferrer nofollow">Jennifer Smith-Parker</a>, Director of Insights, BioSpace Guests<a href="https://www.linkedin.com/in/indunavar/" rel="noopener noreferrer nofollow">⁠Indu Navar⁠</a>, CEO and Founder, EverythingALS<a href="https://www.linkedin.com/in/olga-uspenskaya-cadoz-9b413260/" rel="noopener noreferrer nofollow">Dr. Olga Uspenskaya</a>, Chief Medical Officer, VectorY Therapeutics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.